Aveva Drug Delivery Systems Introduces Generic Fentanyl Patch, Expanding Pain Management Options

Introduction

Aveva Drug Delivery Systems, a division of DifGen, has announced the launch of its generic Fentanyl Transdermal Patch, a significant advancement in pain management solutions in the U.S. This launch marks the third successful introduction of a complex transdermal drug product by the company in just 15 months, highlighting its commitment to improving treatment options for patients living with chronic pain.

Product Overview

The new Fentanyl TDS is specifically designed as a prescription 3-day patch for managing moderate to severe chronic pain. Acting as a generic alternative to Duragesic®, the product fills a critical gap in the market, offering an extended-release opioid analgesic for patients requiring long-term pain management. With U.S. sales for similar products reaching approximately $182 million, the demand for effective pain relief methods has never been more apparent.

Focus on Quality and Safety

Aveva's complex production process involved rapid sourcing and seamless integration of advanced manufacturing equipment. This sophisticated technology is not just about improving production efficiency; it also ensures adherence to strict regulatory and operational standards. The manufacturing facilities are equipped to produce high-quality products, emphasizing patient safety and efficacy.

Addressing Chronic Pain Challenges

Mr. Ramandeep Singh Jaj, the Founder and Co-CEO of DifGen Pharmaceuticals, emphasized the importance of accessible pain management options. "Chronic pain significantly impacts quality of life. Our goal is to provide patients and healthcare providers with reliable solutions that reduce consistent supply disruptions, which often lead to cyclical shortages in the healthcare system."

Dr. Santhanakrishnan Srinivasan, also a Founder and Co-CEO at DifGen, noted the challenges posed by opioid medications, such as potential misuse. The Fentanyl patch incorporates matrix-based technology designed to deter abuse while simultaneously offering consistent, effective relief for chronic pain sufferers. Available in various strengths ranging from 12.5mcg to 100mcg, the product allows for personalized pain management tailored to individual patient needs.

Commitment to Responsible Use

Designed with an advanced adhesive technology, the patch ensures not only comfort and durability but also integrates a tamper-evident feature to promote responsible opioid use. As the opioid crisis continues to be a pressing public health issue, Aveva's commitment to innovation in product safety is commendable. By employing these modern technologies, the company aims to mitigate risks associated with opioid addiction while providing much-needed support for patients.

Company Background

DifGen Pharmaceuticals is dedicated to developing complex pharmaceutical products with a primary focus on accessibility and quality. The company tackles high barriers to entry in the pharmaceutical landscape to ensure that vital medications are within reach for those who need them most. The diverse expertise within its team allows DifGen to address unique challenges related to product development across various therapeutic areas, including a range of dosage forms such as injectables, ophthalmics, and topical products.

Aveva Drug Delivery Systems, as a subsidiary, specializes in sterile products, transdermal delivery systems, and oral dissolvable films. Located in Miramar, Florida, Aveva operates across multiple licensed facilities and has the capacity to produce approximately 500 million patches per year. Its state-of-the-art manufacturing capabilities allow for the handling of sterile solutions and various dosage forms, ensuring high-quality production standards.

Conclusion

The launch of Aveva's generic Fentanyl Transdermal Patch marks a significant step forward in pain management solutions, reflecting a growing need for reliable treatment options. With an ongoing commitment to innovation and quality, both Aveva and DifGen are poised to make valuable contributions to the healthcare system, particularly in addressing the complexities of chronic pain and the challenges associated with opioid use.

For more information about the new Fentanyl TDS and other products offered by Aveva, please visit their official website or contact their customer service.